Johnson DE
Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada.
ArticleKetamine
Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial.
ArticlePsilocybin
Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.
ArticleMDMA
The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression.
ArticlePsilocybin
Psychedelics as a potential treatment for borderline personality disorder: A narrative review.
ArticlePsilocybin
Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy.
ArticleKetamine
A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?
ArticlePsilocybin
Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial.
ArticlePsilocybin
Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude.
ArticlePsilocybin
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder.
ArticlePsilocybin
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
ArticleKetamine